Led by $150m venture financing of WuXi Diagnostic Investment (Cayman ), total medical devices industry venture financing deals worth $912.88m were announced in Asia-Pacific in Q1 2021, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 37.04% over the previous quarter and a drop of 19.9% when compared with the last four-quarter average of $1.14bn.
Asia-Pacific held a 19.85% share of the global medical devices industry venture financing deal value that totalled $4.6bn in Q1 2021. With a 19.35% share and deals worth $889.91m, China was the top country in Asia-Pacific’s venture financing deal value across medical devices industry.
In terms of deal activity, Asia-Pacific recorded 55 deals during Q1 2021, marking a decrease of 35.29% over the previous quarter and a drop of 35.10% over the last four-quarter average. China recorded 48 deals during the month.
Asia-Pacific medical devices industry venture financing deals in Q1 2021: Top deals
The top five venture financing deals accounted for 51.03% of the overall value during Q1 2021.
The combined value of the top five medical devices venture financing deals stood at $465.85m, against the overall value of $912.88m recorded for the quarter.
The top five medical devices deals of Q1 2021 tracked by GlobalData were:
3) Alwin Capital , BioTrack Capital , Kangji Medical Holdings, LYFE Capital , Poly (Hengqin) Capital Management, Sanzheng Health Investment , Shanghai Guohe Modern Service Industry Equity Investment Management and Vertex Ventures China’s $92.6m venture financing of Shenzhen Jingfeng Medical Technology
4) The $76.9m venture financing of Shanghai Hanyu Medical Technology by E Fund Management , Highlight Capital (China), Jiangsu Ruihua Investment Holding , Linden Asset Group , Octagon Capital Group and YF Capital